Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (161-170 of 266) with videos related to

Pageof 27
Sort By:
Cancers|June 10, 2023
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial CarcinomaNataliya Mar, Yousef Zakharia, Alejandro Falcon, et al.
European Urology Oncology|February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS TrialBernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
European Urology Focus|July 30, 2017
Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell CancerEnrique González-Billalabeitia, Juan Manuel Sepúlveda, Pablo Maroto, et al.
Scientific Reports|November 19, 2017
Urothelial cancer proteomics provides both prognostic and functional informationGuillermo de Velasco, Lucia Trilla-Fuertes, Angelo Gamez-Pozo, et al.
Urologic Oncology|October 30, 2024
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, et al.
British Journal of Clinical Pharmacology|January 14, 2022
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapyRonald de Wit, Thomas Powles, Daniel Castellano, et al.
European Urology Focus|November 10, 2020
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract CarcinomaJens Bedke, Axel S Merseburger, Yohann Loriot, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
Urologic Oncology|May 15, 2026
Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective studyPatricia Rioja, Carolina Passarella, Martín Angel, et al.
Pageof 27

Showing results (161-170 of 266) with videos related to

Sort By:
Pageof 27
Cancers|June 10, 2023
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial CarcinomaNataliya Mar, Yousef Zakharia, Alejandro Falcon, et al.
European Urology Oncology|February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS TrialBernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
European Urology Focus|July 30, 2017
Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell CancerEnrique González-Billalabeitia, Juan Manuel Sepúlveda, Pablo Maroto, et al.
Scientific Reports|November 19, 2017
Urothelial cancer proteomics provides both prognostic and functional informationGuillermo de Velasco, Lucia Trilla-Fuertes, Angelo Gamez-Pozo, et al.
Urologic Oncology|October 30, 2024
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, et al.
British Journal of Clinical Pharmacology|January 14, 2022
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapyRonald de Wit, Thomas Powles, Daniel Castellano, et al.
European Urology Focus|November 10, 2020
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract CarcinomaJens Bedke, Axel S Merseburger, Yohann Loriot, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
Urologic Oncology|May 15, 2026
Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective studyPatricia Rioja, Carolina Passarella, Martín Angel, et al.
Pageof 27